Sysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report) shares shot up 8.6% during trading on Monday . The company traded as high as $9.7495 and last traded at $9.7495. 422 shares changed hands during trading, a decline of 100% from the average session volume of 245,966 shares. The stock had previously closed at $8.98.
Wall Street Analyst Weigh In
Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.
Check Out Our Latest Stock Report on Sysmex
Sysmex Stock Up 3.2%
Sysmex (OTCMKTS:SSMXY – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, equities research analysts anticipate that Sysmex Corporation ADR will post 0.42 EPS for the current fiscal year.
Sysmex Company Profile
Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.
The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.
Featured Articles
- Five stocks we like better than Sysmex
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
